< back to News

The IMPACT-AML project participated in the annual European LeukemiaNet (ELN) Symposium, held on March 3, 2026, at the Congress Center Rosengarten in Mannheim, Germany. The ELN is an international network of excellence bringing together approximately 220 centers across 45 countries, with over 1,000 researchers and clinicians, and serves as the leading reference point for cooperative leukemia research worldwide. The annual Symposium is the network’s key instrument of integration: a meeting held at no cost for participants, designed to foster mutual knowledge, trust and collaboration among research groups, with the ultimate goal of accelerating progress in the cure of leukemia.

At the Mannheim Symposium, a dedicated session, titled Emerging Therapies AML 2, chaired by Christoph Röllig, Gerwin Huls and Giovanni Martinelli, was entirely devoted to the IMPACT-AML EU Project. Prof Giovanni Martinelli opened the session with a presentation on the project’s overview and vision, while Dr Christian Junghanß addressed the topic of AML neglected cohorts. From the CRO, Dr Chiara Zingaretti then provided key updates on the IMPACT-AML Trial and STREAM registry, reporting on the current status of the clinical study and the progress of the open collaborative platform for harmonized data collection on R/R AML patients across European centres. Prof Giovanni Marconi presented on Tambiciclib in Ven+Aza early resistant AML within the SURPASS study, followed by a lecture of Dr Vittoria Raimondi, who addressed the critical topic of overcoming venetoclax resistance in AML. The session concluded with an open forum involving all participants to discuss future collaborative projects within the IMPACT-AML framework.

The prominent presence of IMPACT-AML at the ELN Symposium, alongside sessions on the updated ELN Guidelines on AML MRD, Generative AI and Synthetic Data for AML, and the Real-World Data Registry, confirms the project’s growing role within the European translational research landscape.